Related Experiment Video

Updated: Jun 27, 2026

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
11:59

In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus

Published on: April 28, 2023

[Nifedipine antihypertensive treatment effects in pre-eclampsia]

Alex R De Souza1, Melania R Amorim, Aurélio R Costa

  • 1Centro de Atenção à Mulher, Setor de Medicina Fetal, Instituto Materno Infantil Fernando Figueira, Recife, Brasil.

Acta Medica Portuguesa
|December 20, 2008
PubMed

Insights

Antihypertensive treatment for pre-eclampsia is debated. Nifedipine, a calcium channel blocker, shows safety and effectiveness for severe hypertension during pregnancy, with benefits for the maternal-fetal binomial.

Area of Science:

  • Obstetrics and Gynecology
  • Cardiology
  • Pharmacology

Context:

  • Pre-eclampsia management remains controversial regarding antihypertensive treatment benefits.
  • Established cardiovascular benefits exist for non-pregnant patients, but evidence in pre-eclampsia is limited.
  • Various antihypertensive medications are available for use during pregnancy.

Purpose:

  • To review the literature on antihypertensive treatment in pre-eclampsia, specifically evaluating nifedipine.
  • To assess the safety, efficacy, and effectiveness of nifedipine in managing hypertension during pregnancy.
  • To determine appropriate indications for antihypertensive therapy in pre-eclampsia.

Summary:

  • Calcium channel blockers, like nifedipine, are considered second-line treatments.
  • Recent research indicates nifedipine offers improved safety and effectiveness for the maternal-fetal dyad in hypertensive pregnancies.
  • The review concludes that antihypertensive treatment should be reserved for severe and emergency hypertensive cases.

Impact:

  • Nifedipine can be safely utilized for antihypertensive treatment in pregnant patients without significant complications.
  • Provides evidence-based guidance for clinicians managing hypertension in pre-eclampsia.
  • Contributes to optimizing maternal and fetal outcomes in pregnancies complicated by hypertension.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...